Noom is the latest digital health company to jump into the off-label weight loss drug market to make medications more ...

Novo Nordisk ... the company to force Novo Nordisk’s North America operations chief, Doug Langa, to be available to answer questions at the Health, Education, Labor and Pensions (HELP ...

Novo Nordisk and NanoVation will collaborate on two lead programs to develop base-editing therapies for certain rare genetic diseases. NanoVation’s lcLNP technology has demonstrated the ability ...

Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to collaborate on up to seven programs built on technology for targeting ...

Bagsværd, Denmark, 16 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament ...

Novo Nordisk's weight-loss drugs, Ozempic and Wegovy, have multiple positive catalysts, making NVO stock attractive for medium-to-long term investors. Insurance coverage for Ozempic and Wegovy may ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Ahead of a Senate hearing next week at which Novo Nordisk’s CEO has been called to testify, health committee chair Bernie Sanders is keeping the heat on the company. Since April of this year ...

In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve more than 13% weight loss, but that has been over much longer time ...

Sept 17 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of price negotiations ...

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes ...